跳至主要内容
临床试验/EUCTR2019-001725-27-DE
EUCTR2019-001725-27-DE进行中(未招募)1 期

A randomized, open, three-arm comparative study of modern methods of postoperative pain therapy in patients with knee endoprostheses.

Martin-Luther-Universität Halle-Wittenberg0 个研究点目标入组 120 人开始时间: 2019年5月29日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Age: from 18 years
  • - Indication for implantation of a unilateral knee endoprosthesis
  • - Patients with (American Society of Anesthesiologists) ASA Score 1 to 3
  • - Signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 80

排除标准

  • - other endoprosthesis on a lower extremity with NRS > 4
  • - Patients with a previous spinal surgery
  • - inflammatory bowel diseases
  • - permanent intake of opioids WHO stage III (more than 6 weeks before the planned surgery)
  • - clinically relevant Obstructive Sleep Apnea Syndrome
  • - disorders of bone marrow function (e.g. after cytostatic treatment) or diseases of the haematopoietic system
  • - genetically determined glucose-6-phosphate dehydrogenase deficiency
  • - acute intermittent hepatic porphyria
  • - serious impairment of lung function, clinically relevant COPD, Cor pulmonale
  • - severe bronchial asthma, severe coagulation disorders or other contraindications to the development of peripheral nerve block
  • - active peptic ulcers or gastrointestinal (GI) bleeding
  • - allergies or intolerances to sufentanil and oxycodone
  • - Allergies or hypersensitivities to amide-type local anesthetics
  • - Allergies or hypersensitivities to the active ingredients of parecoxib and metamizole
  • - Decompensated or inadequately treated heart failure (NYHA III to IV), clinically newly proven coronary artery disease within the last 6 months, peripheral arterial occlusive disease and/or cerebrovascular events within the last 6 months
  • - considerable hypotension and bradycardia as well as severe prostate hyperplasia and biliary tract diseases
  • - Infection at the injection site for regional anesthesia
  • - Cirrhosis of the liver Child-Pugh Grade B and C
  • - GFR < 30
  • - pregnant or breastfeeding patients
  • - women capable of giving birth without contraception; all measures with a Pearl index <1 are regarded as reliable contraception, other methods such as natural contraception are regarded as inadequate contraception.
  • - Refusal of aaspiration by the patient
  • - Patients unable to consent
  • - Participation in another drug study
  • - officially and/or legally accomodated persons

研究者

相似试验